GT BIOPHARMA, INC. Proceeds from Notes Payable
GT BIOPHARMA, INC. (GTBP) reported Proceeds from Notes Payable of $1.20 million for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-10.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2021-12-29
- GT BIOPHARMA, INC. proceeds from notes payable for the quarter ending 2021-09-30 was $0.00.
- GT BIOPHARMA, INC. proceeds from notes payable for the quarter ending 2021-06-30 was -$5.00K, a 100.03% decline year-over-year.
- GT BIOPHARMA, INC. proceeds from notes payable for the quarter ending 2021-03-31 was $1.21M, a 502.50% increase year-over-year.
- GT BIOPHARMA, INC. proceeds from notes payable for the quarter ending 2020-12-31 was $6.87M, a 3337.00% increase year-over-year.
- GT BIOPHARMA, INC. proceeds from notes payable for fiscal 2020 was $12.53M, a 255.29% increase from fiscal 2019.
- GT BIOPHARMA, INC. proceeds from notes payable for fiscal 2019 was $3.53M, a 76.71% decline from fiscal 2018.
- GT BIOPHARMA, INC. proceeds from notes payable for fiscal 2018 was $15.14M, a 152.80% increase from fiscal 2017.
- GT BIOPHARMA, INC. proceeds from notes payable for fiscal 2017 was $5.99M, a 214.98% increase from fiscal 2016.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 6 month as first filed | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|---|
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2021-11-10 | -$5.00K derived: sum of 2 quarters · filed 2021-12-29 | $1.20M 10-Q · filed 2021-11-10 | $8.07M derived: sum of 4 quarters · filed 2021-12-29 | |
| 2021-06-30 | -$5.00K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2021-12-29 | $1.20M 10-Q/A · filed 2021-12-29 | $8.07M derived: sum of 3 quarters · filed 2021-12-29 | -$2.57M derived: sum of 4 quarters · filed 2021-12-29 | |
| 2021-03-31 | $1.21M 10-Q · filed 2021-05-17 | $8.08M derived: sum of 2 quarters · filed 2021-05-17 | -$2.56M derived: sum of 3 quarters · filed 2021-05-17 | $13.54M derived: sum of 4 quarters · filed 2021-12-29 | |
| 2020-12-31 | $6.87M derived: 10-K 12 month − 10-Q 9 month · filed 2021-04-16 | -$3.77M derived: sum of 2 quarters · filed 2021-04-16 | $12.33M derived: sum of 3 quarters · filed 2021-12-29 | $12.53M 10-K · filed 2021-04-16 | |
| 2020-09-30 | -$10.64M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2020-11-13 | $5.46M derived: sum of 2 quarters · filed 2021-12-29 | $5.66M 10-Q · filed 2020-11-13 | $5.86M derived: sum of 4 quarters · filed 2021-12-29 | |
| 2020-06-30 | $16.10M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2021-12-29 | $16.30M 10-Q/A · filed 2021-12-29 | $4.46M 10-Q · filed 2020-08-14 | $16.50M derived: sum of 3 quarters · filed 2021-12-29 | $17.48M derived: sum of 4 quarters · filed 2021-12-29 |
| 2020-03-31 | $200.00K 10-Q · filed 2021-05-17 | $400.00K derived: sum of 2 quarters · filed 2021-05-17 | $1.38M derived: sum of 3 quarters · filed 2021-05-17 | $2.67M derived: sum of 4 quarters · filed 2021-05-17 | |
| 2019-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-04-16 | $1.18M derived: sum of 2 quarters · filed 2021-04-16 | $2.48M derived: sum of 3 quarters · filed 2021-04-16 | $3.53M 10-K · filed 2021-04-16 | |
| 2019-09-30 | $975.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2020-11-13 | $2.27M derived: sum of 2 quarters · filed 2020-11-13 | $3.33M 10-Q · filed 2020-11-13 | $3.43M derived: sum of 4 quarters · filed 2020-11-13 | |
| 2019-06-30 | $1.30M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2020-08-18 | $2.35M 10-Q/A · filed 2020-08-18 | $2.45M derived: sum of 3 quarters · filed 2020-08-18 | $10.44M derived: sum of 4 quarters · filed 2020-08-18 | |
| 2019-03-31 | $1.05M 10-Q · filed 2020-05-15 | $1.15M derived: sum of 2 quarters · filed 2020-05-15 | $9.14M derived: sum of 3 quarters · filed 2020-05-15 | $9.14M derived: sum of 4 quarters · filed 2020-05-15 | |
| 2018-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $8.09M derived: sum of 2 quarters · filed 2020-03-27 | $8.09M derived: sum of 3 quarters · filed 2020-03-27 | $15.14M 10-K · filed 2020-03-27 | |
| 2018-09-30 | $7.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $7.99M derived: sum of 2 quarters · filed 2019-11-14 | $15.04M 10-Q · filed 2019-11-14 | $15.04M derived: sum of 4 quarters · filed 2019-11-14 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $7.05M 10-Q · filed 2019-08-14 | $7.05M derived: sum of 3 quarters · filed 2019-08-14 | $11.98M derived: sum of 4 quarters · filed 2019-08-14 | |
| 2018-03-31 | $7.05M 10-Q · filed 2019-05-15 | $7.05M derived: sum of 2 quarters · filed 2019-05-15 | $11.98M derived: sum of 3 quarters · filed 2019-05-15 | $12.18M derived: sum of 4 quarters · filed 2019-05-15 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | $4.93M derived: sum of 2 quarters · filed 2019-03-29 | $5.13M derived: sum of 3 quarters · filed 2019-03-29 | $5.99M 10-K · filed 2019-03-29 | |
| 2017-09-30 | $4.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $5.13M derived: sum of 2 quarters · filed 2018-11-14 | $5.99M 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | $195.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $1.06M 10-Q · filed 2018-08-14 | |||
| 2017-03-31 | $866.00K 10-Q · filed 2018-05-15 | ||||
| 2016-12-31 | $1.90M 10-K · filed 2018-03-01 | ||||
| 2015-12-31 | $3.85M 10-K/A · filed 2018-02-28 | ||||
| 2014-12-31 | $2.59M 10-K/A · filed 2018-02-28 | ||||
| 2013-12-31 | $433.00K 10-K · filed 2015-03-31 | ||||
| 2012-12-31 | $315.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-01-08 | $522.00K derived: sum of 2 quarters · filed 2015-01-08 | $930.00K 10-K · filed 2015-01-08 | ||
| 2012-09-30 | $207.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2012-11-21 | $615.00K 10-Q · filed 2012-11-21 | |||
| 2012-06-30 | $408.00K 10-Q/A · filed 2012-09-13 | ||||
| 2011-12-31 | $356.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-11-18 | $356.00K derived: sum of 2 quarters · filed 2014-11-18 | $977.00K 10-K · filed 2014-11-18 | ||
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2012-11-21 | $621.00K 10-Q · filed 2012-11-21 | |||
| 2011-06-30 | $621.00K 10-Q/A · filed 2012-09-13 | ||||
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-21 | $0.00 10-Q · filed 2011-11-21 | |||
| 2010-06-30 | $0.00 10-Q/A · filed 2011-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |